Manufacturing
18 articles in the Manufacturing category
Ozempic Manufacturing News: Eli Lilly vs. Novo Nordisk and the New Competitive Moat
Recent reports suggest that manufacturing capacity has become a key battleground for Eli Lilly and Novo Nordisk in the GLP-1 space. This analysis explores how production scale and supply chain improvements may shape the competitive landscape for peptide-based therapies.
6 min read
Piramal Pharma Solutions Expands Peptide API Manufacturing Facility
Piramal Pharma Solutions has announced an expansion of its peptide active pharmaceutical ingredient (API) facility, according to Contract Pharma. The move underscores the company's commitment to meeting growing demand for peptide-based therapies. Details on the scope and timeline of the expansion were not disclosed in the initial report.
5 min read
RBC Capital Reaffirms Buy on Polypeptide Group, Lowers Price Target to $54.33
RBC Capital has maintained its Buy rating on Polypeptide Group AG (PLYGF.US) while reducing the price target to $54.33. The adjustment reflects updated expectations for the peptide CDMO's performance. Investors continue to watch the stock amid evolving market conditions.
5 min read
Lilly Expands Korea Obesity Drug Supply Chain With SK, Peptron
Eli Lilly is building an obesity drug manufacturing belt in Korea as SK boosts active pharmaceutical ingredient output and Peptron prepares to fill doses. The moves aim to strengthen supply for weight-loss treatments in the region.
5 min readSemaglutide Manufacturing News: Torrey Pines Advances Ultra-Long-Acting Peptides
Torrey Pines Medicine secures angel funding to develop next-generation ultra-long-acting peptide therapeutics, potentially impacting semaglutide manufacturing. Early reports suggest the company is focusing on extended-release formulations, though details remain limited. This analysis explores what the investment means for peptide researchers and the broader GLP-1 landscape.
4 min readFDA Panel Recommends Semax for Pharmacy Compounding: Manufacturing News
An FDA advisory panel has recommended the peptide Semax be added to the pharmacy compounding list, a move that could expand access for researchers. The decision comes amid broader discussions about peptide regulation, including a vote against emideltide. This semax manufacturing news highlights shifting industry dynamics.
4 min readTesamorelin Manufacturing News: Peptide CDMO Market to Reach $11.42B by 2035
The peptide and oligonucleotide CDMO market is projected to reach USD 11.42 billion by 2035, driven by regulatory shifts and increased demand for research compounds. Recent FDA panel recommendations to ease restrictions on peptides like BPC-157 and tesamorelin signal potential manufacturing expansion. This analysis explores capacity changes and industry implications.
6 min readSamsung Proposes Offer to Acquire Swiss CDMO Specializing in Peptides
Samsung has reportedly proposed an offer to acquire PolyPeptide, a Swiss contract development and manufacturing organization (CDMO) specializing in peptide synthesis. The potential acquisition signals growing industry interest in peptide manufacturing capacity and regulatory compliance with FDA standards.
3 min read
Samsung Biologics Eyes $1.8B PolyPeptide Buyout for Obesity Push
Samsung Biologics is reportedly pursuing a $1.8 billion acquisition of PolyPeptide Group to expand its presence in the obesity drug market. The deal would give Samsung Biologics access to PolyPeptide's peptide manufacturing capabilities, which are critical for producing GLP-1 receptor agonists used in weight-loss treatments.
6 min read
Samsung Considers $1.8 Billion Acquisition of Swiss CDMO PolyPeptide
Samsung is reportedly targeting Swiss contract development and manufacturing organization (CDMO) PolyPeptide in a deal valued at approximately $1.8 billion, according to European Biotechnology Magazine. The potential acquisition would mark a significant expansion for Samsung into the peptide manufacturing sector, leveraging PolyPeptide's established capabilities in the production of therapeutic peptides.
6 min readSamsung Biologics Acquires Global Peptide CDMO Company
Samsung Biologics has acquired a global peptide consignment development and production (CDMO) company, according to a report from 매일경제. The acquisition marks a strategic expansion for the South Korean biopharmaceutical giant into the peptide therapeutics manufacturing space. No financial terms or the name of the acquired company were disclosed in the initial report.
5 min readSamsung Biologics Acquires Swiss CDMO for Obesity Drug Production
Samsung Biologics has acquired a Swiss contract development and manufacturing organization (CDMO) specializing in obesity drugs. The deal, reported by 조선일보 on July 20, 2026, marks a strategic expansion into the growing market for weight-loss therapeutics. Financial terms of the acquisition were not disclosed in the initial report.
5 min readAPAC Peptide Capacity Expansion: A High-Stakes Manufacturing Gamble
BioPharma APAC reports that the Asia-Pacific region is undertaking a significant gamble by rapidly expanding peptide manufacturing capacity. This strategic move aims to capture a larger share of the global peptide drug market but carries substantial financial and operational risks. The article examines the drivers, challenges, and potential outcomes of this capacity buildout.
5 min readAscletis Submits Two IND Applications to U.S. FDA for Obesity Treatment
Ascletis has submitted two Investigational New Drug applications to the U.S. FDA for obesity treatments: ASC36, a once-monthly peptide amylin receptor agonist, and ASC36_35 FDC, a co-formulation of ASC36 plus a peptide GLP-1R/GIPR agonist. This manufacturing update signals expanded capacity for peptide-based therapies in metabolic disease.
4 min read
AlphaValue/Baader Europe Adjusts Bachem Price Target and Estimates Before H1 Results
AlphaValue/Baader Europe has revised its price target and financial estimates for Bachem, a peptide contract development and manufacturing organization (CDMO), ahead of the company's first-half 2026 results. The adjustments reflect updated expectations for the company's performance in the coming reporting period.
2 min read
Bora Acquires MacroGenics Manufacturing for $122.5M
Bora has agreed to purchase MacroGenics' clinical and commercial drug substance production portfolio for $122.5 million upfront. West Pharma has reported a cybersecurity attack. Additional updates cover Bavarian Nordic and OrganaBio's new CDMO subsidiary.
1 min readBachem's Strong Performance Hides Analyst Caution Amid Dividend Rise
Bachem has delivered a strong run in its performance. This success covers up caution expressed by analysts. A recent dividend hike stands as a counterpoint to those concerns.
1 min readBacteria Peptide AurB Stops Prostate Tumor Growth via Mitochondria
A peptide derived from bacteria, known as aurB, prevents prostate tumor growth. It achieves this by interfering with mitochondrial energy production. This finding comes from research highlighted in recent reports.
2 min readOther categories